hemostasis

By Targets:	5-HT Receptor (1) AMPK (2) Biochemical Assay Reagents (1) Endogenous Metabolite (1) Factor VIII (1) Factor Xa (3) IGF-1R (2) Mitophagy (2) MMP (3) PARP (1) Phospholipase (1) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (1) Thrombin (1) Transglutaminase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (13) Endocrinology (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Disintegrants (1) Emulsifiers (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131722

EA4	Phospholipase	Cardiovascular Disease
EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA₂ with a K_i value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis .

HY-15827

NSC 405020 1 Publications Verification	MMP	Cardiovascular Disease Cancer
NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis .

HY-N2138

Buddlejasaponin IVb	Others	Inflammation/Immunology
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-B0149

Tranexamic acid 1 Publications Verification cyclocapron	IGF-1R AMPK MMP Mitophagy	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-10563

Sarpogrelate MCI-9042 free acid	5-HT Receptor	Infection
Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT₂ receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-162363

MD6a	PARP	Neurological Disease
MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect .

HY-E70393H

Human Factor XIIIa	Transglutaminase	Others
Human Factor XIIIa is a transglutaminase, which catalyzes the cross-linking of proteins and stabilizes the blood clots. Human Factor XIIIa protects the clots from degradation by fibrinolytic enzymes, which is important for maintaining hemostasis and preventing excessive bleeding .

HY-P10577

RAG8 peptide	Protease Activated Receptor (PAR)	Cardiovascular Disease
RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research .

HY-B1074

Ethamsylate Etamsylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .

HY-137431

Asundexian 1 Publications Verification BAY-2433334	Factor Xa	Cardiovascular Disease
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

HY-B0149R

Tranexamic acid (Standard) cyclocapron (Standard)	IGF-1R AMPK MMP Mitophagy	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (Standard) is the analytical standard of Tranexamic acid. This product is intended for research and analytical applications. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-B1074R

Ethamsylate (Standard) Etamsylate (Standard)	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ethamsylate (Standard) is the analytical standard of Ethamsylate. This product is intended for research and analytical applications. Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .

HY-Y1365

Gelatins	Biochemical Assay Reagents	Metabolic Disease Cancer
Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy ^[1][2][3].

HY-125856

Milvexian 1 Publications Verification BMS-986177; JNJ-70033093	Factor Xa	Cardiovascular Disease
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the K_i of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .

HY-125856A

Milvexian TFA BMS-986177 TFA; JNJ-70033093 TFA	Factor Xa	Cardiovascular Disease
Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .

Cat. No.	Product Name	Type

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Biochemical Assay Reagents
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-Y1365

Gelatins	Thickeners
Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy ^[1][2][3].

Gelatins

Thickeners

Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy ^[1][2][3].

Cat. No.	Product Name	Target	Research Area

HY-P10577

RAG8 peptide	Protease Activated Receptor (PAR)	Cardiovascular Disease
RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research .

Cat. No.	Product Name	Target	Research Area

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2138

Buddlejasaponin IVb	Triterpenes Prosopis juliflora (Sw.) DC. Classification of Application Fields Terpenoids Labiatae Dipsacaceae Source classification Plants Dipsacus asper Inflammation/Immunology Disease Research Fields	Others
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

Cat. No.	Product Name		Classification

HY-Y1365

Gelatins		Emulsifiers Disintegrants
Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy ^[1][2][3].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.

hemostasis

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products